Major medical databases were searched together with reference lists from eligible articles. A narrative approach was used to synthesise the findings and quality assessment was guided by recommendations by Drummond’s 10-point checklist for reporting health economic evaluations.
Results:
The Angiogenesis inhibitor review yielded five cost-effectiveness studies. Most interventions showed improvements in some psychological outcomes. Three studies
reported slightly but not significantly higher health-care costs for their intervention than their comparison groups. Costs of the interventions ranged from US$47 to $629 per patient. One study of patients with mixed cancer diagnoses used the preferred outcome “”quality-adjusted life years”" (QALY) and found a cost-effective investment for an intensive nurse-led program with reported incremental costs of 5278 pound per QALY gained. No study undertook a comprehensive sensitivity analysis Selleck Tyrosine Kinase Inhibitor Library although two studies performed simple one-way sensitivity analyses.
Conclusion:
Current results are inconclusive due to study heterogeneity and inadequate analyses but suggest that psychosocial interventions are inexpensive on a per patient basis. Future studies should routinely include preference-based utility instruments to capture psychological distress in economic evaluation.”
“Purpose: To quantify fluorine 18 ((18)F) fluorodeoxyglucose (FDG) uptake in the Bax apoptosis palatine tonsils
to identify a sensitive and specific metric for distinguishing physiologic asymmetric uptake from squamous cell carcinoma (SCC).
Materials and Methods: This HIPAA-compliant retrospective study was approved by institutional review board. Informed consent requirements were waived. Twenty-six patients (seven female, 19 male; mean age, 53.46 years +/- 10.45 [standard deviation]) with tonsillar SCC were included. Twenty-six patients (seven female, 19 male;
mean age, 61.77 years +/- 10.12) with head and neck carcinomas not involving the tonsils were included as control subjects. Tonsil standardized uptake values (SUVs) were measured bilaterally in each group. Independent-samples t test was used to compare mean SUVs, and Pearson correlation was used to evaluate association of FDG uptake between tonsils within control subjects.
Results: The mean maximum SUV (SUV(max)) of tonsil tumors was 9.36 +/- 4.54, which was significantly higher than that of contralateral cancer-free tonsils (2.54 +/- 0.88; P < .0001) and tonsils in control subjects (2.98 +/- 1.08; P < .0001). In patients with tonsillar cancer, the mean difference in SUV(max) between tonsils was 10.43 +/- 7.07, which was significantly greater than that in control subjects (0.62 +/- 0.54; P < .0001). The mean SUV(max) ratio between tonsils in patients with carcinoma was 3.79 +/- 1.69, which was threefold higher than in control subjects (1.18 +/- 0.13; P < .0001).